JP2020526196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526196A5 JP2020526196A5 JP2019572719A JP2019572719A JP2020526196A5 JP 2020526196 A5 JP2020526196 A5 JP 2020526196A5 JP 2019572719 A JP2019572719 A JP 2019572719A JP 2019572719 A JP2019572719 A JP 2019572719A JP 2020526196 A5 JP2020526196 A5 JP 2020526196A5
- Authority
- JP
- Japan
- Prior art keywords
- glycoprotein
- glycan
- ornithine
- putrescine
- glycans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 claims 32
- 108090000288 Glycoproteins Proteins 0.000 claims 32
- 238000000034 method Methods 0.000 claims 23
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 22
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 12
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 12
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 12
- 229960003104 ornithine Drugs 0.000 claims 12
- 235000010469 Glycine max Nutrition 0.000 claims 11
- 244000068988 Glycine max Species 0.000 claims 11
- 239000005700 Putrescine Substances 0.000 claims 11
- 241000894007 species Species 0.000 claims 7
- 108010081667 aflibercept Proteins 0.000 claims 6
- 229960002833 aflibercept Drugs 0.000 claims 6
- 108010046141 rilonacept Proteins 0.000 claims 6
- 229960001886 rilonacept Drugs 0.000 claims 6
- 108010008165 Etanercept Proteins 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- 229960000403 etanercept Drugs 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 4
- 239000006143 cell culture medium Substances 0.000 claims 3
- 102000035122 glycosylated proteins Human genes 0.000 claims 3
- 108091005608 glycosylated proteins Proteins 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021111482A JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529471P | 2017-07-06 | 2017-07-06 | |
| US62/529,471 | 2017-07-06 | ||
| US201862625744P | 2018-02-02 | 2018-02-02 | |
| US62/625,744 | 2018-02-02 | ||
| PCT/US2018/040734 WO2019010191A1 (en) | 2017-07-06 | 2018-07-03 | CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111482A Division JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Division JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526196A JP2020526196A (ja) | 2020-08-31 |
| JP2020526196A5 true JP2020526196A5 (https=) | 2021-08-12 |
| JP7265494B2 JP7265494B2 (ja) | 2023-04-26 |
Family
ID=64904487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572719A Active JP7265494B2 (ja) | 2017-07-06 | 2018-07-03 | 糖タンパク質を作製するための細胞培養方法 |
| JP2021111482A Pending JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Active JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A Active JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A Pending JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111482A Pending JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Active JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A Active JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A Pending JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20190010531A1 (https=) |
| EP (2) | EP3967765A1 (https=) |
| JP (5) | JP7265494B2 (https=) |
| KR (4) | KR20210084695A (https=) |
| CN (3) | CN118878651A (https=) |
| AU (4) | AU2018298039B2 (https=) |
| BR (1) | BR112020000127A2 (https=) |
| CA (1) | CA3067847A1 (https=) |
| IL (2) | IL326217A (https=) |
| MX (2) | MX2020000228A (https=) |
| SG (1) | SG11201912548XA (https=) |
| TW (2) | TWI910092B (https=) |
| WO (1) | WO2019010191A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US10961500B1 (en) * | 2019-04-23 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Cell culture medium for eukaryotic cells |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN113679744B (zh) * | 2020-05-18 | 2023-12-29 | 中国人民解放军军事科学院军事医学研究院 | 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途 |
| CN114058673A (zh) * | 2021-09-15 | 2022-02-18 | 江苏先思达生物科技有限公司 | 一种脂肪肝检测试剂及其在脂肪肝检测中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| AT409379B (de) * | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2002069733A1 (en) * | 2001-03-05 | 2002-09-12 | Council Of Scientific And Industrial Research | Process for preparation of protein-hydrolysate from soy flour |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
| US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
| US20060094104A1 (en) * | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| US7642078B2 (en) * | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
| ES2474573T3 (es) * | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2008154014A2 (en) * | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| MX2010000970A (es) | 2007-07-31 | 2010-03-09 | Regeneron Pharma | Anticuerpos humanos contra cd20 humano y metodo para utilizarlos. |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN101603026B (zh) * | 2009-06-19 | 2011-01-19 | 华东理工大学 | 适于动物细胞产品生产的无动物来源低蛋白培养基 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CN104962539B (zh) * | 2009-07-31 | 2019-09-17 | 百深公司 | 用于adamts蛋白表达的细胞培养基 |
| CN102115728B (zh) * | 2009-12-31 | 2012-09-26 | 北京清大天一科技有限公司 | 无血清动物细胞培养基干粉、液体培养基及其制备方法 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| AU2011296702A1 (en) * | 2010-08-31 | 2013-03-21 | Friesland Brands B.V. | Culture medium for eukaryotic cells |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| KR20140097245A (ko) * | 2011-10-31 | 2014-08-06 | 머크 샤프 앤드 돔 코포레이션 | 개선된 특성을 갖는 항체의 제조 방법 |
| DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
| KR102063028B1 (ko) | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| BR112014031842B1 (pt) * | 2012-06-21 | 2020-09-15 | Baxalta GmbH | Método para remover um contaminante viral de uma preparação |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| AU2013298521A1 (en) * | 2012-08-02 | 2015-02-26 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
| US9540449B2 (en) | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| US20160237400A1 (en) * | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
| AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| EP2968454B1 (en) | 2013-03-15 | 2019-02-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| CA2908407C (en) * | 2013-05-29 | 2022-06-14 | F. Hoffmann-La Roche Ag | Quantitative control of sialylation |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| BR122020004385B1 (pt) * | 2014-01-13 | 2022-10-04 | Amgen Inc | Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP6632984B2 (ja) | 2014-03-11 | 2020-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| JP7093612B2 (ja) | 2014-05-27 | 2022-06-30 | アカデミア シニカ | Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法 |
| MA40021A (fr) * | 2014-06-03 | 2015-12-10 | Lupin Ltd | Processus de culture cellulaire destiné à produire une protéine |
| CN107001461A (zh) | 2014-09-16 | 2017-08-01 | 瑞泽恩制药公司 | 抗胰高血糖素抗体及其使用方法 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| TWI734775B (zh) * | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
-
2018
- 2018-07-03 BR BR112020000127-9A patent/BR112020000127A2/pt unknown
- 2018-07-03 WO PCT/US2018/040734 patent/WO2019010191A1/en not_active Ceased
- 2018-07-03 IL IL326217A patent/IL326217A/en unknown
- 2018-07-03 KR KR1020217020548A patent/KR20210084695A/ko not_active Ceased
- 2018-07-03 US US16/026,539 patent/US20190010531A1/en not_active Abandoned
- 2018-07-03 TW TW107122944A patent/TWI910092B/zh active
- 2018-07-03 CA CA3067847A patent/CA3067847A1/en active Pending
- 2018-07-03 SG SG11201912548XA patent/SG11201912548XA/en unknown
- 2018-07-03 AU AU2018298039A patent/AU2018298039B2/en active Active
- 2018-07-03 EP EP21196848.2A patent/EP3967765A1/en active Pending
- 2018-07-03 CN CN202411053765.1A patent/CN118878651A/zh active Pending
- 2018-07-03 KR KR1020247012715A patent/KR102782655B1/ko active Active
- 2018-07-03 JP JP2019572719A patent/JP7265494B2/ja active Active
- 2018-07-03 KR KR1020257008109A patent/KR20250041082A/ko active Pending
- 2018-07-03 TW TW114106933A patent/TW202526028A/zh unknown
- 2018-07-03 CN CN201880045238.2A patent/CN110914293B/zh active Active
- 2018-07-03 KR KR1020207000732A patent/KR102659791B1/ko active Active
- 2018-07-03 MX MX2020000228A patent/MX2020000228A/es unknown
- 2018-07-03 CN CN202111031466.4A patent/CN114075269A/zh active Pending
- 2018-07-03 EP EP18827553.1A patent/EP3649144A4/en active Pending
-
2019
- 2019-12-18 IL IL271524A patent/IL271524A/en unknown
-
2020
- 2020-01-08 MX MX2024013233A patent/MX2024013233A/es unknown
- 2020-01-14 US US16/742,723 patent/US20200131554A1/en not_active Abandoned
- 2020-05-01 US US16/864,689 patent/US20200255880A1/en not_active Abandoned
-
2021
- 2021-07-05 JP JP2021111482A patent/JP2021166537A/ja active Pending
- 2021-08-23 US US17/409,193 patent/US20210388408A1/en not_active Abandoned
- 2021-08-23 US US17/409,158 patent/US20210388407A1/en active Pending
- 2021-09-06 AU AU2021229121A patent/AU2021229121A1/en not_active Abandoned
-
2023
- 2023-01-18 JP JP2023005801A patent/JP7525672B2/ja active Active
- 2023-05-01 AU AU2023202659A patent/AU2023202659B2/en active Active
-
2024
- 2024-07-18 JP JP2024114751A patent/JP7736872B2/ja active Active
-
2025
- 2025-04-30 AU AU2025203053A patent/AU2025203053A1/en active Pending
- 2025-08-28 JP JP2025142351A patent/JP2025172879A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526196A5 (https=) | ||
| Hirahara et al. | Helper T‐cell differentiation and plasticity: insights from epigenetics | |
| JP2022503959A5 (https=) | ||
| LeMessurier et al. | Influenza A virus directly modulates mouse eosinophil responses | |
| Lacruz et al. | Identification of novel candidate genes involved in mineralization of dental enamel by genome‐wide transcript profiling | |
| ATE462000T1 (de) | Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin | |
| RU2010108308A (ru) | Способ получения гетерогенных белков | |
| JP2006500907A5 (https=) | ||
| BRPI0612273B8 (pt) | anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição | |
| EA200970263A1 (ru) | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков | |
| Yamamoto et al. | Does genetic predisposition contribute to the exacerbation of COVID-19 symptoms in individuals with comorbidities and explain the huge mortality disparity between the East and the West? | |
| RU2017105260A (ru) | Фермент лизосомальной болезни накопления | |
| RU2011142793A (ru) | Полученная из микроорганизма протеаза усовершенствованного типа, обеспечивающая свертывание молока | |
| JP2005502319A5 (https=) | ||
| WO2024015875A3 (en) | Determination of protein information by recoding amino acid polymers into dna polymers | |
| WO2005010023A3 (en) | Method for prediction of an epitope | |
| ATE502305T1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
| JP2010538089A5 (https=) | ||
| EA200600554A1 (ru) | Способ получения рекомбинантных белков | |
| CN110684736A (zh) | 一种基于CRISPR-Cas9编辑技术的敲除鸡Shp-2基因的细胞系及其构建方法 | |
| Bruel et al. | Epithelial induction of porcine suppressor of cytokine signaling 2 (SOCS2) gene expression in response to Entamoeba histolytica | |
| JP2024523166A5 (https=) | ||
| EP2517002A4 (en) | SRM / MRM TEST ON INSULIN RECEPTOR SUBSTRATE-1 PROTEIN (IRS1) | |
| ATE445009T1 (de) | Signalpeptid zur herstellung eines polypeptids | |
| CN1493687A (zh) | 白细胞介素-15基因修饰的自然杀伤细胞株及其制备方法 |